Skip to content
10-Q

Quarterly Report

FILANA THERAPEUTICS, INC. FLNA

0001437749-26-015664

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 48.31M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$8.88M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$11.34M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $86.57M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $95.5M
Stockholders Equity Q1 2026 · Mar 31, 2026 $68.14M
Stockholders Equity Q1 2026 · Dec 31, 2025 $74.4M
Stockholders Equity Q1 2026 · Mar 31, 2025 $127.62M
Stockholders Equity Q1 2026 · Dec 31, 2024 $145.7M
Current Liabilities Q1 2026 · Mar 31, 2026 $40.12M
Current Liabilities Q1 2026 · Dec 31, 2025 $43.83M
Total Liabilities Q1 2026 · Mar 31, 2026 $40.23M
Total Liabilities Q1 2026 · Dec 31, 2025 $43.95M
Current Assets Q1 2026 · Mar 31, 2026 $87.96M
Current Assets Q1 2026 · Dec 31, 2025 $97.71M
Total Assets Q1 2026 · Mar 31, 2026 $108.37M
Total Assets Q1 2026 · Dec 31, 2025 $118.36M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.21
Eps Basic Q1 2026 · Mar 31, 2025 −$0.48
Sga Expense Q1 2026 · Mar 31, 2026 $6.62M
Sga Expense Q1 2026 · Mar 31, 2025 $10.92M
Rd Expense Q1 2026 · Mar 31, 2026 $4.54M
Rd Expense Q1 2026 · Mar 31, 2025 $13.67M
Net Income Q1 2026 · Mar 31, 2026 −$10.33M
Net Income Q1 2026 · Mar 31, 2025 −$23.4M
Operating Income Q1 2026 · Mar 31, 2026 −$11.17M
Operating Income Q1 2026 · Mar 31, 2025 −$24.59M